LPIN1 and obesity due to melanocortin 4 receptor deficiency: Due to its effects on hepatic oxidative capacity, circulating TG and free fatty acid levels, LPIN-1 has been suggested as a potential therapeutic target for obesity-related dyslipidaemia and NAFLD [30].